PP
ABBV icon

PagnatoKarp Partners’s AbbVie ABBV Stock Holding History

PagnatoKarp Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,201
Closed -$203K – 193
2018
Q4 		$203K Buy
+2,201
New +$194K 0.04% 142
2018
Q2 		– Sell
-2,327
Closed -$220K – 149
2018
Q1 		$220K Buy
+2,327
New +$256K 0.09% 117

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PagnatoKarp Partners's ABBV Position: Q1 2019 in Review

PagnatoKarp Partners sold out of AbbVie (ABBV) in Q1 2019, closing a stake of 2,201 shares — an estimated $203K sold.

PagnatoKarp Partners first reported a position in ABBV in Q1 2018 and held it in 2 quarters. The position peaked at $220K in Q1 2018. 2,034 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

  • PagnatoKarp Partners reported no remaining AbbVie position as of Q1 2019 after selling out during the quarter.
  • PagnatoKarp Partners sold 2,201 AbbVie shares in Q1 2019, an estimated $203K.
  • PagnatoKarp Partners first reported a position in AbbVie in Q1 2018 and held it in 2 quarters.
  • PagnatoKarp Partners's AbbVie position peaked at $220K in Q1 2018.
  • 2,034 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on PagnatoKarp Partners's 13F filing for Q1 2019, filed 10 Apr 2019.